Dyne Therapeutics, Inc. (DYN) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Dyne Therapeutics, Inc. (DYN) Healthcare & Pipeline Overview

Dyne Therapeutics, Inc., a biotechnology firm specializing in muscle disease therapeutics, leverages its FORCE platform to target genetically driven conditions like myotonic dystrophy and Duchenne muscular dystrophy. With a focus on innovative delivery methods, Dyne aims to address unmet needs in rare skeletal, cardiac, and metabolic muscle diseases, positioning itself within the competitive biotechnology landscape.

What Is the Investment Thesis for DYN?

Dyne Therapeutics presents a notable research candidate due to its innovative FORCE platform and focus on genetically driven muscle diseases. The platform's ability to deliver disease-modifying therapeutics directly to muscle tissue addresses a critical challenge in treating these conditions. Key value drivers include the advancement of its pipeline programs for DM1, DMD, and FSHD, with clinical trial results serving as potential catalysts. The company's market capitalization of $3.40B reflects investor confidence in its technology and pipeline. However, potential risks include clinical trial failures, regulatory hurdles, and competition from other biotechnology companies developing similar therapies. Successful execution of clinical programs and strategic partnerships will be crucial for Dyne to realize its full potential.

Based on FMP financials and quantitative analysis

DYN Key Highlights

Dyne Therapeutics focuses on genetically driven muscle diseases, a niche market with significant unmet medical needs.

• The FORCE platform enhances the delivery of disease-modifying therapeutics directly to muscle tissue, potentially improving treatment efficacy.
• The company's pipeline includes programs for myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral dystrophy (FSHD).
• Dyne's market capitalization is $3.40B as of 2026-05-10, reflecting investor confidence in its technology and pipeline.
• Dyne Therapeutics has 192 employees, indicating a focused and specialized workforce.

Who Are DYN's Competitors?

DYN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are DYN's Key Strengths?

Proprietary FORCE platform for targeted drug delivery.

• Focus on genetically driven muscle diseases with high unmet need.
• Strong intellectual property portfolio.
• Experienced management team.

What Are DYN's Weaknesses?

Reliance on the success of its clinical pipeline.

• High research and development costs.
• Limited commercialization experience.
• Competition from larger pharmaceutical companies.

What Could Drive DYN Stock Higher?

Clinical trial readouts for DM1 program in Q4 2026.

• Initiation of Phase 2 clinical trial for DMD program in Q1 2027.
• Advancement of FSHD program through preclinical development.
• Expansion of FORCE platform to new therapeutic targets.
• Potential for strategic partnerships and collaborations.

What Are the Key Risks for DYN?

Negative return on equity (-58.3%) — the business is not currently generating profit on shareholder capital.

• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Insider selling — insiders were net sellers of roughly $121.6M recently.
• Clinical trial failures or delays.
• Regulatory hurdles and delays in obtaining marketing approvals.
• Competition from other biotechnology companies developing similar therapies.
• Patent challenges and intellectual property disputes.
• High research and development costs.

What Are the Growth Opportunities for DYN?

• Expansion of FORCE Platform Applications: Dyne can expand the application of its FORCE platform to address a broader range of genetically driven diseases beyond its current focus. This includes exploring new therapeutic areas and targets within muscle diseases, as well as potentially extending the platform to other tissue types. The market for targeted drug delivery technologies is estimated to reach $100 billion by 2030, offering significant growth potential. Timeline: Ongoing, with continuous research and development efforts.
• Advancement of Clinical Pipeline: Dyne's most immediate growth opportunity lies in advancing its clinical pipeline programs for DM1, DMD, and FSHD. Positive clinical trial results and regulatory approvals would drive significant value creation. Each of these indications represents a multi-billion dollar market opportunity. Timeline: Near-term, with clinical trial readouts expected over the next 2-3 years.
• Strategic Partnerships and Collaborations: Dyne can leverage strategic partnerships and collaborations with larger pharmaceutical companies to accelerate the development and commercialization of its therapeutics. These partnerships can provide access to additional funding, expertise, and market reach. The value of such partnerships can range from millions to billions of dollars, depending on the scope and terms of the agreement. Timeline: Ongoing, with potential for new partnerships in the next 1-2 years.
• Geographic Expansion: Dyne can expand its geographic presence beyond the United States to address the global market for muscle disease therapeutics. This includes establishing operations in Europe, Asia, and other regions with significant patient populations. The global market for rare disease treatments is estimated to reach $200 billion by 2028. Timeline: Mid-term, with potential for international expansion in the next 3-5 years.
• Development of Next-Generation FORCE Platform: Dyne can continue to innovate and develop next-generation versions of its FORCE platform to further enhance its capabilities and address new challenges in drug delivery. This includes improving targeting specificity, reducing off-target effects, and expanding the range of therapeutic modalities that can be delivered. The market for advanced drug delivery technologies is constantly evolving, with ongoing advancements in materials science, nanotechnology, and biotechnology. Timeline: Long-term, with continuous research and development efforts.

What Are DYN's Competitive Advantages?

• Proprietary FORCE platform for targeted drug delivery.
• Strong intellectual property portfolio protecting its therapeutics and technologies.
• Expertise in developing treatments for genetically driven muscle diseases.
• Established relationships with key opinion leaders and patient advocacy groups.

What Does DYN Do?

Dyne Therapeutics, Inc. is a biotechnology company founded in 2017 and headquartered in Waltham, Massachusetts. The company is dedicated to developing innovative therapeutics for genetically driven muscle diseases. Dyne's core technology is its proprietary FORCE platform, which is designed to enhance the delivery of disease-modifying therapeutics directly to muscle tissue. This platform is being utilized to develop treatments for a range of conditions, including myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral dystrophy (FSHD), as well as other rare skeletal muscle, cardiac, and metabolic muscle diseases. The company's focus is on addressing the underlying genetic causes of these diseases, aiming to provide more effective and durable treatments than currently available. By improving the delivery of therapeutic oligonucleotides, Dyne seeks to overcome the limitations of traditional drug development approaches in muscle diseases. The FORCE platform represents a significant advancement in targeted drug delivery, potentially transforming the treatment landscape for patients with these debilitating conditions. Dyne's pipeline includes multiple programs in various stages of development, reflecting its commitment to advancing novel therapies for a broad spectrum of muscle disorders. The company's strategic focus on genetically driven muscle diseases positions it within a competitive but highly specialized segment of the biotechnology industry. Dyne's innovative approach to drug delivery and its commitment to addressing unmet medical needs differentiate it from other companies in the field.

What Products and Services Does DYN Offer?

• Develop therapeutics for genetically driven muscle diseases.
• Utilize the FORCE platform to deliver disease-modifying treatments.
• Target conditions like myotonic dystrophy type 1 (DM1).
• Develop treatments for Duchenne muscular dystrophy (DMD).
• Create therapies for facioscapulohumeral dystrophy (FSHD).
• Address rare skeletal muscle diseases.
• Develop treatments for cardiac and metabolic muscle diseases.

How Does DYN Make Money?

• Develops proprietary therapeutics for muscle diseases.
• Out-licenses or co-develops its therapeutics with pharmaceutical partners.
• Generates revenue through milestone payments and royalties.
• Focuses on research and development to create new therapies.

What Industry Does DYN Operate In?

Dyne Therapeutics operates within the biotechnology industry, specifically targeting the genetic causes of muscle diseases. The industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The market for muscle disease therapeutics is growing, driven by advances in genetic research and increasing awareness of rare diseases. Dyne's FORCE platform positions it to compete with companies developing gene therapies and other targeted treatments. Competitors such as CELC: Celcuity Inc., CGON: CG Oncology Inc, CNTA: Centessa Pharmaceuticals plc, MIRM: Mirum Pharmaceuticals, Inc., and APGE: Apogee Therapeutics, Inc. also operate in the broader biotechnology space, but Dyne's focus on muscle diseases differentiates it.

Who Are DYN's Key Customers?

• Patients with genetically driven muscle diseases.
• Healthcare providers who treat these patients.
• Pharmaceutical companies seeking to license or co-develop therapeutics.
• Payers (insurance companies and government healthcare programs) who reimburse for these treatments.

Dyne Therapeutics, Inc. (DYN) Valuation Context

Valued at $3.40B, DYN is classified as a mid-cap stock. Analyst price targets span from $24.00 to $50.00, with a consensus of $33.71. At the current price of $18.21, that implies approximately 85% upside potential. Relative to its peer group, DYN's quantitative score of 48/100 is below the peer average of 71/100.

DYN Revenue & Earnings Trend

In Q2 FY2026, DYN generated $0 in top-line revenue. The company recorded a net loss of $178.6M, with diluted EPS of $-1.08. Quarter-over-quarter revenue has been mixed, typical for a mid-cap company operating in Healthcare. Across the four most recent quarters, DYN averaged $-0.86 in diluted EPS.

Company Profile

Dyne Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Waltham, US. The company is led by CEO John G. Cox. DYN has traded publicly since 2020.

Return on equity for Dyne Therapeutics, Inc. stands at -58.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -41.8%, showing how much profit it generates from its asset base. Its free cash flow yield is -12.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 19.92 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -12.3%, the inverse of the P/E and a quick read on earnings relative to price.

Dyne Therapeutics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 4.07 places it in the safe zone, indicating low near-term bankruptcy risk.

Dyne Therapeutics, Inc. has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 10.4% below estimates on average.

Over the past six months, Dyne Therapeutics, Inc. insiders filed 99 SEC Form 4 transactions — 87 sales and 12 purchases. On net that is roughly 5.2M shares disposed (about $121.6M), a signal worth weighing alongside the fundamentals.

DYN Financials

DYN Latest News

DYN Analyst Consensus

DYN MoonshotScore

What Investors Ask About Dyne Therapeutics, Inc. (DYN) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources